medvi

MEDVi is the purest expression of AI transforming a hot consumer market. A solo founder leveraged AI tools to launch a telehealth platform connecting patients to compounded semaglutide and tirzepatide, exploding from hundreds of customers in early months to hundreds of thousands and $401 million in 2025 revenue with just two full-time employees. This creates unmatched scalability and profitability in a cash-pay weight loss boom...

Position: Long 12m Target: N/A Catalyst: Continued patient growth and revenue trajectory toward the projected $1.8 billion run-rate in 2026, plus any further validation of the AI-driven model through media or partner disclosures. Primary Risk: Regulatory disruption from FDA enforcement on compounded GLP-1s, including potential restrictions on marketing or dispensing that halt the core offering. Exit Trigger: Material FDA action that meaningfully restricts compounded semaglutide/tirzepatide availability or mass telehealth marketing, or clear evidence of patient churn and slowing acquisition as branded options improve.

MEDVI operates a telehealth platform facilitating access to compounded GLP-1 medications such as semaglutide and tirzepatide through independent licensed providers and pharmacies on a cash-pay subscription model. No revenue, gross margin, operating margin, or net margin trends are available from audited EDGAR filings or the provided source snapshot. Without disclosed figures for any fiscal period, you can't evaluate operating leverage, contribution margins from subscription renewals, or year-over-year changes...

No balance sheet items, including total assets, total debt, net debt, current assets, or liabilities, are disclosed in the source snapshot or EDGAR-referenced data for MEDVI. Consequently, standard metrics such as debt/EBITDA, interest coverage, current ratio, or quick ratio cannot be calculated or trended. There is no evidence of covenant compliance, off-balance-sheet arrangements, or overall financial leverage...

The source data provides no cash flow statement details, operating cash flow, free cash flow (FCF), capital expenditures, or working capital changes for MEDVI. FCF conversion from net income, capex intensity as a percentage of revenue, and cash conversion cycle metrics are therefore unavailable. In a subscription-based telehealth model reliant on pharmacy partnerships, cash flow visibility would normally highlight collection efficiency and reinvestment needs...

All of MEDVi's 2025 revenue came from its GLP-1 telehealth offering built around compounded semaglutide and related weight-loss programs. The platform hit $401 million in sales by adding customers quickly through AI-powered marketing and onboarding. It went from just 300 customers in the first month to 1,000 in the second and reached 250,000 cumulative by the end of the year...

The limited data you have points to solid implied unit economics in MEDVi's first year. Revenue of $401 million spread across 250,000 customers gives an average revenue per user of roughly $1,604. Programs start at $179 for the first month of semaglutide, which covers physician review, the plan, and the medication...

The compounded GLP-1 telehealth market is contestable . Plenty of firms run similar low-barrier setups: they use technology platforms to link patients with third-party licensed prescribers like OpenLoop Health and compounding pharmacies. A new player could copy MEDVi's lean approach (reportedly just 2 full-time employees backed by AI and partnerships) without needing much of its own infrastructure...

MEDVi demonstrates high operational leverage with reported $401M in 2025 sales achieved via a lean team of 2 full-time employees, relying on AI/automation and third-party partnerships rather than owned fixed-cost infrastructure. Fixed cost intensity appears low in owned assets (no significant R&D, distribution networks, or lumpy capital disclosed), with costs variable through outsourced prescribing and compounding. Minimum Efficient Scale (MES) is not a large fraction of the market for any single player; new entrants can achieve similar efficiency quickly via similar partnership models without reaching massive volume...

MEDVi's bottom-up sizing starts with observed early traction: 300 customers in month one scaling rapidly, pricing from $179/month for compounded semaglutide (no contract), and reported 2025 sales of $401 million with only two full-time employees. Assumptions include high operating leverage from AI tools enabling low customer acquisition costs, retention supporting repeat revenue, and affordability driving volume in an obesity-affected U.S. adult population exceeding 110 million...

Industry-wide GLP-1 penetration for weight loss remains low despite ~40% U.S. adult obesity prevalence: approximately 12% of adults reported use in late 2025, with many more eligible but constrained by cost or access. Branded options face high list prices; compounded/telehealth alternatives like MEDVi's $179 starting point target the affordability gap...

MEDVi works as a telehealth facilitator instead of making drugs or running a full pharmacy. You see the company use AI to handle customer sign-ups, connect patients with clinicians, customize plans, and manage support. This setup reportedly drove $401 million in 2025 revenue while keeping staff very small, around two full-time employees...

You won't find any formal R&D pipeline, clinical trial results, or timelines in the sources that are out there. MEDVi doesn't make or mix the drugs itself. Instead it focuses on helping people get existing compounded GLP-1 receptor agonists, with semaglutide starting at $179 for the first month and refills at $299...

MEDVi shows no patents, no protected trade secrets with real staying power, and no other IP holdings in the data that's available. With zero patents listed and no specifics on any unique algorithms, the main advantages come down to moving fast, the founders' hands-on AI work, and the network that grows as patient numbers climb past 500,000. You can't estimate how many years of protection might exist because there are no filings or court cases to review...

MEDVi keeps things asset-light with no manufacturing or inventory of its own. It counts on partnerships with multiple USA-certified compounding pharmacies to fill orders for compounded GLP-1 medications. The company says it meets with these partners regularly to track shortages, shipping delays, and quality testing...

Everything from sourcing ingredients to final fulfillment runs through U.S.-licensed and FDA-registered organizations, so there's no direct exposure to international markets or tariffs on finished goods. The active ingredients used in compounding come from FDA-registered suppliers that are likely based in or meet U.S. standards...

The biggest catalysts for MEDVi tie back to regulatory changes because the business simply facilitates access to compounded semaglutide and tirzepatide. 1. FDA enforcement actions or API restrictions (est...

Over Q2 and Q3 2026, keep an eye on patient acquisition numbers and any follow-up messages from the FDA about compounded GLP-1 marketing. You want to see steady or rising monthly new patients (described as scaling into the thousands) rather than churn picking up if branded supply problems fade. Also watch gross margin stability in this cash-pay setup and any hints of too much reliance on certain compounding pharmacies...

STREET SAYS: No consensus estimates, price targets, or forward-looking metrics show up in public sources. Analyst coverage looks nonexistent, with no Buy/Hold/Sell ratings, EPS projections, or revenue forecasts linked to audited numbers. This gap remains even though the company's website claims more than 500,000 patients and lists compounded semaglutide programs starting at $179 for the first month and $299 for refills as of early 2026...

You won't find any recent upgrades, downgrades, or estimate revisions here, since the snapshot shows zero confirmed analyst estimates or coverage at all. Trends in revenue, EPS, or other metrics stay untrackable without any baseline numbers to work from. This total blank spot means you can't spot any momentum in Street sentiment around MEDVi's compounded GLP-1 offerings, like its physician-supervised programs for semaglutide and tirzepatide...

MEDVi runs a lean telehealth platform that delivers clinician-guided compounded GLP-1 weight-loss solutions. Reports say the company leans heavily on AI for its operations and customer service. Public sources identify Matthew Gallagher, age 41, as the founder who started MEDVi from his Los Angeles home with $20,000 in initial capital alongside his brother...

The source snapshot discloses no board composition, director independence metrics, or shareholder rights details such as voting provisions or anti-takeover measures. Typical EDGAR filings like 10-K Item 10 or DEF 14A would cover board size, independence classification, and committee structures, but none show up here. This leaves you with uncertainty around oversight quality for a company in the highly regulated telehealth and compounded pharmaceutical environment...

No compensation data, including salary, bonus, equity grants, or performance hurdles, is available from the source snapshot or any referenced DEF 14A equivalent. You can't perform a standard pay-for-performance analysis, such as checking alignment of incentives with revenue growth, patient outcomes, or long-term shareholder value in the GLP-1 space. There are no disclosed details on stock ownership guidelines, clawback provisions, or whether variable pay ties to metrics like margin expansion or regulatory compliance...

MEDVi's business model as a telehealth platform facilitating access to compounded GLP-1 medications (semaglutide, tirzepatide) via independent clinicians and partner pharmacies suggests potential sensitivity to interest rates through consumer discretionary spending and funding costs, though you have no specific data. No balance sheet, debt mix (floating vs fixed), or free cash flow duration shows up in available filings...

MEDVi works mainly as a patient management and telehealth facilitation platform rather than a direct manufacturer or heavy user of physical commodities. Key inputs likely include pharmaceutical compounding ingredients for GLP-1 medications and operational costs (software, clinician networks), but you don't see any a portion of COGS breakdowns or specific commodity exposures (e.g., active pharmaceutical ingredients, energy) in available filings. Hedging programs aren't confirmed...

Tariff exposure isn't quantified by product or region, since no revenue segmentation or supply chain details appear. China supply chain dependency for compounded GLP-1 ingredients or related components isn't disclosed, though many pharmaceutical supply chains have some international element. Potential margin impact under various tariff scenarios (e.g., 10-60% on imports) stays unmodelable without cost structure data...

MEDVi provides no public disclosures on key shareholder rights provisions such as poison pills, classified boards, dual-class share structures, majority vs. plurality voting standards, or proxy access rights. No history of shareholder proposals or related outcomes is available snapshot...

No accruals ratio, auditor continuity details, revenue recognition policies, off-balance-sheet items, or related-party transaction disclosures are available for MEDVi. The source hierarchy (SEC EDGAR audited > market data > computed ratios) yields zero filings containing financial statements, internal control assessments, or auditor opinions. As a telehealth platform facilitating GLP-1 weight-loss programs through partnerships with licensed providers and pharmacies, standard revenue recognition around service fees or medication coordination remains unconfirmed in public records...

MEDVi runs an understandable asset-light telehealth facilitation business. It connects patients to independent clinicians and compounded GLP-1 medications through monthly programs that start at $179 with no long-term contracts. The model focuses on AI-driven efficiency and low overhead, which fits with favorable long-term prospects in the weight-loss sector if regulatory conditions hold steady...

You should keep any position size small, under 1% of your portfolio, because the source data has no audited financials at all. That makes any conviction feel provisional. You'd want to see confirmed 10-K disclosures with sustained gross margins on facilitation fees and patient retention above 60% in the monthly programs before stepping in...

Conviction comes in at 35/100. The asset-light model with minimal headcount and AI support gives some theoretical scalability, but the total lack of confirmed financial metrics drags the score down hard. Pillar scores (1-10, with weights): Business Model Scalability (weight 30%): 6/10 , Directional evidence of efficiency, but unquantified patient retention or unit economics...